Cargando…

Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease

Insulin resistance is a condition in which the target tissues have a decreased response to insulin signaling, resulting in glucose uptake defect, and an increased blood sugar level. Pancreatic beta cells thus enhance insulin production to compensate. This situation may cause further beta cell dysfun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Wei-Ren, Liu, Kuan-Hung, Ling, Tsai-Chieh, Wang, Ming-Cheng, Lin, Wei-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130897/ https://www.ncbi.nlm.nih.gov/pubmed/37122432 http://dx.doi.org/10.4239/wjd.v14.i4.352

Ejemplares similares

Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus
por: Cheng, Chih-Ning, et al.
Publicado: (2020)

Relationship Between Body Mass Index, Antidiabetic Agents, and Midterm Mortality in Patients With Both Type 2 Diabetes Mellitus and Acute Coronary Syndrome
por: Jong, Chien‐Boon, et al.
Publicado: (2019)

Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
por: Wang, Shu-Yi, et al.
Publicado: (2020)

Alterations of Gut Microbiota in Type 2 Diabetes Individuals and the Confounding Effect of Antidiabetic Agents
por: Almugadam, Babiker Saad, et al.
Publicado: (2020)

Dose adjustment of antidiabetic medications in chronic kidney disease
por: Snyder, Matthew Salvatore, et al.
Publicado: (2021)

The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
por: Wu, Chen-Ning, et al.
Publicado: (2020)

Role of red grape polyphenols as antidiabetic agents
por: Pandey, Kanti Bhooshan, et al.
Publicado: (2014)

Sesamin: A Promising Therapeutic Agent for Ameliorating Symptoms of Diabetes
por: Huang, Shu-Ming, et al.
Publicado: (2023)

Cross-Sectional Validation of Diabetes Risk Scores for Predicting Diabetes, Metabolic Syndrome, and Chronic Kidney Disease in Taiwanese
por: Lin, Jou-Wei, et al.
Publicado: (2009)

Development and validation of a risk prediction model for chronic kidney disease among individuals with type 2 diabetes
por: Lin, Cheng-Chieh, et al.
Publicado: (2022)

Leptospirosis kidney disease: Evolution from acute to chronic kidney disease
por: Chou, Li-Fang, et al.
Publicado: (2023)

Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients
por: Lee, Yau-Jiunn, et al.
Publicado: (2020)

Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure
por: Sharma, D. C., et al.
Publicado: (2017)

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
por: Lin, Shih-Yi, et al.
Publicado: (2018)

Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease
por: Kuo, I-Ching, et al.
Publicado: (2016)

Emergence of T cell immunosenescence in diabetic chronic kidney disease
por: Chiu, Yen-Ling, et al.
Publicado: (2020)

Association of Angiopoietin-2 with Renal Outcome in Chronic Kidney Disease
por: Tsai, Yi-Chun, et al.
Publicado: (2014)

The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study
por: Chu, Wei-Min, et al.
Publicado: (2017)

Treatment patterns of antidiabetic and kidney protective therapies among patients with type 2 diabetes mellitus and chronic kidney disease in Colombia. The KDICO descriptive study
por: Machado-Duque, Manuel E, et al.
Publicado: (2023)

Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis
por: Gamble, JM, et al.
Publicado: (2008)

Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
por: Nguyen, Nam Nhat, et al.
Publicado: (2022)

A quality improvement initiative for patients with chronic kidney disease to promote their smoking cessation
por: Chen, Cheng-Hsu, et al.
Publicado: (2023)

Tissue Factor Expression in Obese Type 2 Diabetic Subjects and Its Regulation by Antidiabetic Agents
por: Wang, Jing, et al.
Publicado: (2015)

Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes
por: Tan, Eleonora, et al.
Publicado: (2015)

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
por: Chan, Cheng-Wei, et al.
Publicado: (2018)

Hyperuricemia and diabetes mellitus when occurred together have higher risks than alone on all-cause mortality and end-stage renal disease in patients with chronic kidney disease
por: Li, Cheng-Hung, et al.
Publicado: (2022)

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
por: Tschöpe, Diethelm, et al.
Publicado: (2013)

Comparative effectiveness of incident oral antidiabetic drugs on kidney function
por: Hung, Adriana M, et al.
Publicado: (2012)

Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease
por: Yen, Fu-Shun, et al.
Publicado: (2022)

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
por: Lu, Qingguo, et al.
Publicado: (2019)

Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice
por: Tsai, Hung-Cheng, et al.
Publicado: (2019)

Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study
por: Lin, Shih-Yi, et al.
Publicado: (2022)

Associations among Heavy Metals and Proteinuria and Chronic Kidney Disease
por: Tsai, Hui-Ju, et al.
Publicado: (2021)

ODP632 Preadmission Use Of Antidiabetic Medications And Mortality Among Patients With Covid-19 Having Type 2 Diabetes: A Meta-analysis
por: Nguyen, Nam Nhat, et al.
Publicado: (2022)

Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes
por: Yen, Fu-Shun, et al.
Publicado: (2022)

The Lower Limit of Reference of Urinary Albumin/Creatinine Ratio and the Risk of Chronic Kidney Disease Progression in Patients With Type 2 Diabetes Mellitus
por: Tang, Wei-Hua, et al.
Publicado: (2022)

Renal expression of hypoxia inducible factor-1α in patients with chronic kidney disease: a clinicopathologic study from nephrectomized kidneys
por: Tung-Wei, Hung, et al.
Publicado: (2013)

Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
por: Lin, Kai-Jung, et al.
Publicado: (2021)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

Association between antidiabetic agents use and leukocyte telomere shortening rates in patients with type 2 diabetes
por: Liu, Juanhong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8m2dctcpuv6g6qj9bsi7696382